Biomedical research often focuses on properties that differentiate between diseased and
healthy tissue; one of the current focuses is elevated expression and altered localisation of …

Prostate cancer is a leading cause of cancer death in men worldwide. Among the various
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …

Simple Summary Recent medical advancements have strived for a personalized medicine
approach to patients, aimed at optimizing therapy outcomes with minimum toxicity. In this …

The high incidence and heavy disease burden of prostate cancer (PC) require accurate and
comprehensive assessment for appropriate disease management. Prostate-specific …

Simple Summary Radiolabeled gastrin-releasing peptide receptor (GRPR)-antagonists have
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …

Many low-molecular weight targeted radiotherapeutics (TRTs) are capable of rapidly
achieving exceptional tumor to non-target ratios shortly after administration. However, the …

Our laboratory has previously reported a strategy of employing cysteine cathepsin (CC)
inhibitors as adduct forming, trapping agents to extend the tumor residence time of …

Purpose The development of diagnostic and therapeutic agents utilizing small peptides (eg,
bombesin (BBN)) to target the overexpression of the gastrin-releasing peptide receptor …

Cathepsin B (CTSB) is a lysosomal protease that is overexpressed in tumor cells.
Radioimmunoconjugates (RICs) composed of CTSB‐recognizing chelating agents are …

Angiogenesis, tissue invasion and metastasis in the tumour microenvironment are all critical
hallmarks of cancer. Upregulation of cathepsin L plays an important role in angiogenesis …